Bioweapons research gets quiet OK from National Institutes of Health: Here’s why that could be ‘horrific’

| | March 5, 2019
3-4-2019 h n labvaccinecdc
A Sanofi-developed H7N9 vaccine with a new strain of virus is being tested in two clinical studies sponsored by the National Institutes of Health. Image credit: CDC
This article or excerpt is included in the GLP’s daily curated selection of ideologically diverse news, opinion and analysis of biotechnology innovation.

For more than a decade now, two scientists–one in the U.S. and one in the Netherlands–have been trying to create a deadly human pathogen from avian influenza. That’s right: they are trying to turn “bird flu,” which does not normally infect people, into a human flu.

Not surprisingly, many scientists are vehemently opposed to this.

In response to these and other concerns, in October 2014 the U.S. government called for a “pause” in this dangerous researchNIH Director Francis Collins said that his agency would study the risks and benefits before proceeding further.

Well, four years later, the risks and benefits haven’t changed, but the NIH has (quietly) just allowed the research to start again.

Related article:  How do you 'boost' your body's immune function in the fight against the coronavirus? Answer: You can't

[W]hy the heck would anyone do that? The answers were and still are unsatisfactory: claims such as “we’ll learn more about the pandemic potential of the flu” and “we’ll be better prepared for an avian flu pandemic if one occurs.” These are hand-waving arguments that may sound reasonable, but they promise only vague benefits while ignoring the dangers of this research. If the research succeeds, and one of the newly-designed, highly virulent flu strains escapes, the damage could be horrific.

Read full, original post: Scientists restart bioweapons research, with NIH’s blessing

Share via
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend